Quantcast
Home > Quotes > VRTX
VRTX

Vertex Pharmaceuticals Incorporated Common Stock (VRTX) Quote & Summary Data

$177.38
*  
2.74
1.52%
Get VRTX Alerts
*Delayed - data as of Jul. 20, 2018  -  Find a broker to begin trading VRTX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
200
Today's High / Low
$ 180.14 / $ 176.71
Share Volume
1,517,732
50 Day Avg. Daily Volume
1,641,176
Previous Close
$ 180.12
52 Week High / Low
$ 183.39 / $ 136.50
Market Cap
45,201,786,552
P/E Ratio
206.26
Forward P/E (1y)
92.85
Earnings Per Share (EPS)
$ 0.86
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.24

Intraday Chart

Shares Traded

Share Volume:
1,517,732
50 Day Avg. Daily Volume:
1,641,176

P/E Ratio

P/E Ratio:
206.26
Forward P/E (1y):
92.85
Earnings Per Share (EPS):
$ 0.86

Trading Range

The current last sale of $177.38 is 29.95% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 180.14 $ 183.39
 Low: $ 176.71 $ 136.50

ETFs with VRTX as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
4.33% iShares Nasdaq Biotechnology Index Fund (IBB) +6.86 (6.15%)
1.42% SPDR Series Trust SPDR S&P Biotech ETF (XBI) +7.21 (7.74%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We invest in scientific innovation to create transformative medicines for serious diseases. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other diseases. Our marketed products are ORKAMBI (lumacaftor in combination with ivacaftor), KALYDECO (ivacaftor) and SYMDEKO (tezacaftor in combination with ivacaftor). Cystic Fibrosis Our goal is to develop treatment regimens that will provide benefits to all patients with CF and will enhance the benefits that currently are being provided to patients taking our medicines. Current Medicines ORKAMBI, KALYDECO and SYMDEKO are collectively approved to treat approximately 45% of the 75,000 CF patients in North America, Europe and Australia.  ... More ...  

Risk Grade

Where does VRTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 180.12
Open Date:
Jul. 20, 2018
Close Price:
$ 180.12
Close Date:
Jul. 20, 2018

Consensus Recommendation

Analyst Info